Von Hippel-Lindau gene therapy: A novel strategy in limiting endothelial cell proliferative activity

Annals of Vascular Surgery

Volumn 15, Issue 1, 2001, Pages 1-6

  Jacob, Theresa ^a   Ascher, Enrico ^a   Hingorani, Anil ^a   Gunduz, Yilmaz ^a   Yorkovich, William ^a   Seth, Prem ^b  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b Iowa Cancer Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENE PRODUCT; GREEN FLUORESCENT PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS VECTOR; VON HIPPEL LINDAU PROTEIN;

ADENOVIRUS; AORTA; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE THERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VASCULAR ENDOTHELIUM; VON HIPPEL LINDAU DISEASE;

EID: 0035142221     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100160010011     Document Type: Article

References (28)

1. Cancer. Many vessels, faulty gene
2. VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma
3. The VHL tumour-suppressor gene paradigm
4. Activation of Sp 1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta
5. The vascular endothelial growth factor family of polypeptides
6. Inhibition of transcription elongation by the VHL tumor suppressor protein
7. Recombinant adenovirus expressing Von Hippel-Lindau-mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kipl
8. P53 gene transfer to the injured rat carotid artery promotes apoptosis
9. Effect of p53 gene therapy combined with CTLA4Ig selective immunosuppression on prolonged neointima formation reduction in a rat model
10. p53 gene transfer to the injured rat carotid artery decreases neointimal formation
11. Potential role for retinoic acid receptor-gamma in the inhibition of breast cancer cells by selective retinoids and interferons
12. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors
13. Matrix alters the proliferative response of enterocytes to growth factors
14. Comparison of 3H-thymidine incorporation and CellTiter 96 aqueous colorimetric assays in cell proliferation of bovine mononuclear cells
15. Identification of the von Hippel-Lindau disease tumor suppressor gene
16. Von Hippel-Lindau syndrome. A pleomorphic condition
17. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer
18. Von Hippel-Lindau disease and renal cancer: 10 Years of genetic progress
19. Expression of von Hippel-Lindau protein in normal and pathological human tissues
20. Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent
21. Third International Meeting on von Hippel-Lindau disease
22. Angiogenesis in malignant gliomas
23. Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: An in vivo study on 29 tumors
24. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function
25. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein
26. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene
27. Alternate choice of initiation codon produces a biologically active product of the von Hippel-Lindau gene with tumor suppressor activity
28. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells